Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
16
AFMD Quote, Financials, Valuation and Earnings
Last price:
$1.22
Seasonality move
:
8.1%
Day range:
$1.16 - $1.25
52-week range:
$1.14 - $8.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.08x
P/B ratio:
1.06x
Volume:
251.9K
Avg. volume:
442.8K
1-year change:
-72.28%
Market cap:
$20.3M
Revenue:
$9M
EPS (TTM):
-$4.95
Analysts' Opinion
-
Consensus RatingAffimed NV has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.90, Affimed NV has an estimated upside of 1421.72% from its current price of $1.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.01 representing 100% downside risk from its current price of $1.24.
Fair Value
-
According to the consensus of 6 analysts, Affimed NV has 1421.72% upside to fair value with a price target of $18.90 per share.
AFMD vs. S&P 500
-
Over the past 5 trading days, Affimed NV has underperformed the S&P 500 by -20.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Affimed NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Affimed NV revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Affimed NV reported revenues of $170.5K.
Earnings Growth
-
Affimed NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Affimed NV reported earnings per share of -$1.03.
Enterprise value:
1.5M
EV / Invested capital:
0.05x
Price / LTM sales:
20.08x
EV / EBIT:
--
EV / Revenue:
1.56x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-91.92%
Net Income Margin (TTM):
-7991.63%
Return On Equity:
-158.94%
Return On Invested Capital:
-127.62%
Operating Margin:
-9220.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $43.6M | $19.9M | $949.4K | $2.1M | $170.5K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$91.1M | -$125.3M | -$80M | -$27.1M | -$15.7M | |
| EBITDA | -$79.7M | -$121.9M | -$70.7M | -$25.3M | -$15.9M | |
| Diluted EPS | -$6.25 | -$8.51 | -$4.95 | -$1.77 | -$1.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $119M | $235.8M | $226.6M | $113.1M | $36.2M | |
| Total Assets | $126.7M | $255.6M | $232.4M | $127.5M | $44.6M | |
| Current Liabilities | $53M | $76.9M | $40.1M | $30.6M | $18.7M | |
| Total Liabilities | $71.5M | $100.3M | $54.3M | $46.6M | $25.4M | |
| Total Equity | $55.2M | $155.3M | $178M | $80.9M | $19.2M | |
| Total Debt | $1.5M | $11.8M | $17.7M | $14.4M | $9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$107.4M | -$128.5M | -$83.6M | -$19.8M | -$13.2M | |
| Cash From Investing | $755.7K | -$38.4M | $21.9M | -$40.8M | $7.6M | |
| Cash From Financing | $122.7M | -$1.7M | $839.1K | -$1.7M | $1.4M | |
| Free Cash Flow | -$110.5M | -$132.4M | -$84.2M | -$23.3M | -$13.2M | |
AFMD
Sector
Market Cap
$20.3M
$46.1M
Price % of 52-Week High
13.86%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-12.48%
-0.6%
1-Year Price Total Return
-72.28%
-30.52%
Beta (5-Year)
2.063
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.48
200-day SMA
Sell
Level
$4.39
Bollinger Bands (100)
Sell
Level
2.55 - 4.13
Chaikin Money Flow
Sell
Level
-110M
20-day SMA
Sell
Level
$2.10
Relative Strength Index (RSI14)
Sell
Level
17.07
ADX Line
Sell
Level
19.87
Williams %R
Buy
Level
-94.2608
50-day SMA
Sell
Level
$2.85
MACD (12, 26)
Sell
Level
-0.49
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
174.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.093)
Sell
CA Score
(Annual)
Level (-2.647)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (6.4963)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Stock Forecast FAQ
In the current month, AFMD has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AFMD average analyst price target in the past 3 months is $18.90.
-
Where Will Affimed NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Affimed NV share price will rise to $18.90 per share over the next 12 months.
-
What Do Analysts Say About Affimed NV?
Analysts are divided on their view about Affimed NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Affimed NV is a Sell and believe this share price will drop from its current level to $5.01.
-
What Is Affimed NV's Price Target?
The price target for Affimed NV over the next 1-year time period is forecast to be $18.90 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AFMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Affimed NV is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AFMD?
You can purchase shares of Affimed NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Affimed NV shares.
-
What Is The Affimed NV Share Price Today?
Affimed NV was last trading at $1.22 per share. This represents the most recent stock quote for Affimed NV. Yesterday, Affimed NV closed at $1.24 per share.
-
How To Buy Affimed NV Stock Online?
In order to purchase Affimed NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
